ChargePoint Technology collaborates with STERIS to deliver sterile solution success for Evonik

Liverpool, UK, 11TH OCTOBER: The powder and liquid transfer specialist,  ChargePoint Technology Group, and leading provider of infection prevention and other procedural products and services, STERIS, have partnered to provide a successful sterile solution to specialty chemicals company, Evonik. 

Evonik specialises in complex parenteral medications at its plant in Alabama, USA, where it manufactures using fill-finish lines handling a broad mix of products. 

The company is using ChargePoint’s AseptiSafe® Bio Valve coupled to the STERIS Vaporised Hydrogen Peroxide (VHP®) bio-decontamination system on its VarioSys® filling line. The qualified VarioSys line is optimised for continuous filling, allowing the product to move through the process in the shortest amount of time. The solution also overcomes the challenge of transferring product from a container to the filling equipment while maintaining sterility.

The ChargePoint AseptiSafe Split Butterfly Valve (SBV) secures the connection between the product and the container, protecting the sterility and therefore the performance of the API. 

Chris Eccles, CEO at ChargePoint Technology said: “With the development of specialised medicines increasing, many manufacturers, like Evonik, have struggled to find specialised equipment that meet their requirements. It was absolutely crucial that Evonik could aseptically connect and disconnect the product vessel quickly to maintain product sterility. After reviewing multiple vendors, our system was found to provide the highest degree of product protection.”

STERIS's portable VHP 1000ED bio-decontamination unit decontaminates its surroundings and easily adapts to its manufacturing environment. Together with the ChargePoint technology, the replacement of product containers could occur aseptically and within one hour, as well as enabling continuous filling without interruption, critical to minimising downtime. 

Caroline Hand, Production Engineer at Evonik commented: “Evonik has been delighted by the results produced by the multi-faceted approach from ChargePoint and STERIS. This partnership provided a solution that delivered the highest integrity when performing high volume aseptic product transfer with multiple product containers and significantly reduced the turnaround time of this project. We are thrilled with the outcomes.”

Abby Lovell, Associate Product Manager at STERIS further commented: “Our continued partnership with ChargePoint means that its unique aseptic SBV technology in conjunction with STERIS’s VHP bio-decontamination system are collectively meeting the technical needs of the industry. This has allowed us to provide the ultimate sterile transfer solution to Evonik and we look forward to many more years of partnership”.

ChargePoint Technology offers containment and aseptic transfer valves and single-use solutions that are essential for the safe transfer of powders and liquids during pharmaceutical and biopharmaceutical manufacturing. For more information, pls visit www.thechargepoint.com to find out more about its offerings.

ENDS

About ChargePoint Technology

ChargePoint Technology is the market leader in powder and liquid containment and aseptic transfer valves providing operator safety and sterility assurance for the pharmaceutical, biotech, chemical and other process industries. Its client portfolio includes some of the top 35 pharmaceutical companies and reaches into North America, UK, Europe, Japan, China and India, amongst others.

ChargePoint Technology manufactures its cutting-edge devices in its purpose-built facility in Liverpool, UK, and employs more than 100 employees across the globe to meet the increase in global demand for its products and solutions.

www.thechargepoint.com

About STERIS 

STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare, life sciences and dental products and services.   For more information, visit www.STERIS.com. 

About Evonik

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15 billion and an operating profit (adjusted EBITDA) of €2.38 billion in 2021. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 33,000 employees work together for a common purpose: We want to improve life today and tomorrow. For more information, visit https://corporate.evonik.com/en 

Media contact

Ramarketing PR

Danny McIver- daniel.mciver@ramarketingpr.com